Pharsight

1. Duavee patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7683051	WYETH PHARMS	Crystalline polymorph of bazedoxifene acetate	Mar, 2027 (3 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535	WYETH PHARMS	2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations	May, 2024 (7 months from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Market Authorisation Date: 03 October, 2013

Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE;0.45MG	TABLET;ORAL	Prescription

DUAVEE family patents

2. Protonix patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550153	WYETH PHARMS	Pantoprazole multiparticulate formulations	Sep, 2024 (1 year, 2 days from now)
US7553498	WYETH PHARMS	Pantoprazole multiparticulate formulations	Sep, 2024 (1 year, 2 days from now)
US7838027	WYETH PHARMS	Pantoprazole multiparticulate formulations	Sep, 2024 (1 year, 2 days from now)
US7838027 (Pediatric)	WYETH PHARMS	Pantoprazole multiparticulate formulations	Mar, 2025 (1 year, 6 months from now)
US7553498 (Pediatric)	WYETH PHARMS	Pantoprazole multiparticulate formulations	Mar, 2025 (1 year, 6 months from now)
US7550153 (Pediatric)	WYETH PHARMS	Pantoprazole multiparticulate formulations	Mar, 2025 (1 year, 6 months from now)
US7544370	WYETH PHARMS	Pantoprazole multiparticulate formulations	Jun, 2026 (2 years from now)
US7544370 (Pediatric)	WYETH PHARMS	Pantoprazole multiparticulate formulations	Dec, 2026 (3 years from now)

Drugs and Companies using PANTOPRAZOLE SODIUM ingredient

Market Authorisation Date: 14 November, 2007

Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd

Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg	13 Sep, 2019	1	30 Jun, 2020	07 Jun, 2026	Eligible

Strength	Dosage	Availability
EQ 40MG BASE	FOR SUSPENSION, DELAYED RELEASE;ORAL	Prescription

PROTONIX family patents

3. Protonix Iv patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6780881 (Pediatric)	WYETH PHARMS	Freeze-dried pantoprazole preparation and pantoprazole injection	May, 2022 (1 year, 4 months ago)
US8754108 (Pediatric)	WYETH PHARMS	Freeze-dried pantoprazole preparation and pantoprazole injection	May, 2022 (1 year, 4 months ago)
US7351723 (Pediatric)	WYETH PHARMS	Freeze-dried pantoprazole preparation and pantoprazole injection	May, 2022 (1 year, 4 months ago)

Drugs and Companies using PANTOPRAZOLE SODIUM ingredient

Market Authorisation Date: 22 March, 2001

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg/vial	07 Apr, 2005	1		17 Nov, 2021	Extinguished

Strength	Dosage	Availability
EQ 40MG BASE/VIAL	INJECTABLE;INTRAVENOUS	Prescription

PROTONIX IV family patents

4. Zosyn patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6900184	WYETH PHARMS	Compositions containing pipercillin and tazobactam useful for injection	Apr, 2023 (5 months ago)
US7915229	WYETH PHARMS	Compositions containing piperacillin and tazobactam useful for injection	Apr, 2023 (5 months ago)
US8133883	WYETH PHARMS	Compositions containing piperacillin and tazobactam useful for injection	Apr, 2023 (5 months ago)

Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient

Market Authorisation Date: 22 October, 1993

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.25 g/vial 3.375 g/vial 4.5 g/vial
12 g/1.5 g per vial (pharmacy bulk)	06 Dec, 2011	1	29 Oct, 2014	14 Apr, 2023	Eligible
36 mg/4.5 g per vial (pharmacy bulk)		1	15 Sep, 2009	14 Apr, 2023	Eligible

Strength	Dosage	Availability
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	INJECTABLE;INJECTION	Discontinued
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	INJECTABLE;INJECTION	Discontinued
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	INJECTABLE;INJECTION	Discontinued
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	INJECTABLE;INJECTION	Discontinued

ZOSYN family patents

5. Zosyn In Plastic Container patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8133883	WYETH PHARMS	Compositions containing piperacillin and tazobactam useful for injection	Apr, 2023 (5 months ago)
US6900184	WYETH PHARMS	Compositions containing pipercillin and tazobactam useful for injection	Apr, 2023 (5 months ago)
US7915229	WYETH PHARMS	Compositions containing piperacillin and tazobactam useful for injection	Apr, 2023 (5 months ago)

Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient

Market Authorisation Date: 24 February, 1998

Treatment: Method of treating bacterial infections

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	INJECTABLE;INJECTION	Prescription
EQ 40MG BASE/ML;EQ 5MG BASE/ML	INJECTABLE;INJECTION	Prescription
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	INJECTABLE;INJECTION	Prescription